Chemotherapy for urological cancer : Usefulness and feasibility of current protocols - Abstract

The Department of Urology, Wakayama Medical University, Wakayama 641-0012, Japan.

 

In this symposium, we discussed the usefulness and feasibility of current chemotherapy protocols for urological cancers including renal cell carcinoma, urothelial cancer, prostate cancer and testicular cancer. (1) Renal cell carcinoma : Although molecular targeted therapy is now becoming a standard therapy for metastatic renal cell carcinoma, the current situation is somehow confusing due to unknown adverse effects and lack of guidelines for indication of each compound. (2) Urothelial cancer : gemcitabine and cisplatin (GC) therapy is taking over methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) therapy because of less toxicity. We focused on a novel biomarker, hENT1, to predict the anti tumor effect of GC therapy. (3)Prostate cancer : The survival benefit of docetaxel for castration resistant prostate cancer was proven by large clinical trials. We dealt with uracil and tegafur (UFT) therapy which has been widely used in Japan. (4)Testicular cancer : It is needles to say that BEP therapy was established as a standard induction therapy for metastatic testicular cancer. However, regarding salvage chemotherapy, it is still controversial whether vinblastine, ifosphamide and platinum (VIP), paclitaxel, ifosphamide and platinum (TIP) and high dose chemotherapy should be selected.

Article in Japanese.

Written by:
Hara I, Motoo Y.   Are you the author?

Reference: Hinyokika Kiyo. 2011 Mar;57(3):151-2.

PubMed Abstract
PMID: 21586888

UroToday.com Prostate Cancer Section

 

 

email news signup